*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation
We introduce you to Thomas Hudson, M.D., vice president, head of oncology discovery and early development at AbbVie.